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Abstract DOCK and Affinity studies were carried out to study
the binding of D- and L-penicillamine to the transactivator
protein (tat) of human immunodeficiency virus type 1 (HIV-1).
These studies reveal a selective binding of D-penicillamine to the
cysteine-rich region covering amino acid residues 20^38 of the
tat protein. A careful analysis of the components of the binding
energy of the D- and L-isomers reveals that the D-isomer has a
more favorable van der Waals interaction resulting from an
optimal placement of the dimethylthiomethyl side chain in the
binding site. This observation matches the experimental data
that D-penicillamine is a more potent inhibitor of tat-mediated
transactivation than the L-isomer. The docking and experi-
mental data offer an interesting approach to design structural
molecules with potential application to block signal functions of
the tat protein in HIV-1 pathogenesis. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The tat protein encoded by the human immunode¢ciency
virus type 1 (HIV-1) is a potent transactivator of gene expres-
sion from the viral long terminal repeat (LTR). The domains
that are essential for transactivation, a Pro-xaa3-Pro triad, a
cysteine-rich metal binding sequence motif, and a cluster of
basic residues, are present within the N-terminal 57 residues
of tat protein. In recent years, additional functions for tat
have been detected which are attributed to its extracellular
release from infected cells. Signalling from the extracellular
tat protein can activate a range of cellular genes in uninfected
cells leading to immune suppression and T-cell apoptosis, a
condition commonly found in patients with HIV-1 infection.
The approaches leading to abolish the intracellular and inter-
cellular signalling mechanisms of tat protein, in recent years,
have become a focus of experimentation [1^10]. The ¢rst re-
ported inhibitor of tat-mediated transactivation possessing
anti-HIV activity was D-penicillamine, a structural analog of
cysteine [2]. The present communication is an evidence, based
on DOCK and A⁄nity studies, that D-penicillamine ¢ts in the
tat sequence comprising residues 20^38, whereas the L-isomer
does not exhibit this selectivity. These observations are in
good agreement with the experimental data reported here.
2. Materials and methods
2.1. Materials
The culture medium (RPMI 1640) and fetal calf serum were sup-
plied by Gibco (Eggenstein, Germany). [14C]Acetyl-CoA (4 mCi/
mmol) was obtained from NEN/Dupont (Dreieich, Germany). All
other reagents were analytic-grade obtained from Merck (Darmstadt,
Germany) or from Serva (Heidelberg, Germany). Inhibitors were dis-
solved or diluted in water and stored as stock solutions at 320‡C.
2.2. Plasmids
The tat gene (clone 1) was cloned by way of cDNA cloning, using
poly(A)-selected RNA from HIV-1 (BH 10) infected cells [2,11]. The
HIV-1 LTR-CAT construct was obtained by inserting clone 15 DNA
into pSV0-CAT at the HindIII site [11,12] and the resulting plasmid
was termed pC15CAT. The plasmid pCV1 was obtained by inserting
viral cDNA containing the tat gene (clone 1) into the mammalian
expression vector pCV which contains duplicated SV40 origins of
replication, adenovirus major late promoter, splice sites from adeno-
virus and mouse immunoglobulin genes, mouse dihydrofolate reduc-
tase cDNA, and SV40 polyadenylation signal [11,12]. Plasmids were
isolated according to the alkaline lysis method [13,14] and puri¢ed by
anion-exchange chromatography using Qiagen columns (Qiagen, Hil-
den, Germany).
2.3. Transfection and CAT assay
Jurkat cells (1U107) were washed with serum-free medium and
incubated at 37‡C for 1 h in 1 ml serum-free medium containing 50
mM Tris^HCl (pH 7.3), DEAE-dextran (Mr 500 000, 250 Wl/ml) and
15 Wg of each plasmid DNA, pCV1 and pC15CAT. The cells were
then washed with growth medium (without serum) and incubated in
10 ml serum-containing medium at 37‡C. At this time, the test com-
pounds were added at the desired concentrations in parallel batches.
All transfections were performed in triplicate for each set of experi-
ments. The processing of cell cultures and the procedure of CAT
assays are described in detail elsewhere [7]. Brie£y, 44 h after the
incubation, cells were washed with phosphate-bu¡ered saline and sus-
pended in 80 Wl of 0.25 M Tris^HCl (pH 7.8), and cellular extracts
were prepared by three cycles of freezing (in liquid nitrogen) and
thawing (37‡C). All cellular extracts were adjusted to equal protein
concentration and heated for 15 min at 65‡C to inactivate deacetylases
in the extract. For CAT assays, 30 Wl of the cell extract was mixed
with 20 Wl of 100 mM Tris^HCl (pH 7.8) in a 6 ml glass scintillation
vial. The vial was transferred to a water bath set at 37‡C and 200 Wl of
freshly prepared CAT reaction mixture (100 Wl of 0.25 M Tris^HCl,
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pH 7.8, 50 Wl of 5 mM chloramphenicol, 10 Wl [14C]acetyl-CoA, 0.1
WCi, and 40 Wl water) was added. To this mixture, 5 ml of a water-
immiscible scintillation £uid (Econo£uor, NEN/Dupont) was carefully
overlain and incubated at 37‡C for 4 h.
2.4. Docking studies
The structure of HIV-1 (Zaire-2 isolate) tat determined by nuclear
magnetic resonance and deposited in the Protein Data Bank was used
for docking studies [15]. The protein structure was minimized with the
CVFF force ¢eld [16] with the backbone atoms tethered by a force
constant of 100 kcal/mol/Aî 2 to a gradient of 0.01 kcal/mol/Aî . Dock-
ing of both D- and L-penicillamine was carried out using DOCK 4.0
[17], where rough possible binding sites were discovered, which were
re¢ned by A⁄nity (MSI, USA). This strategy was followed for rea-
sons mentioned below.
To balance between computational time and accuracy, DOCK uses
a very simpli¢ed and approximate scoring function [18]. The program
has been successfully used to generate starting rough binding modes,
which can be further evaluated by other more accurate methods [19].
A⁄nity uses molecular mechanics force ¢eld in both docking and
scoring, besides incorporating solvation e¡ects [20]. This makes A⁄n-
ity accurate at determining and evaluating ¢nal docking conforma-
tions [20]. On the other hand, it is not very e⁄cient in sampling a
large conformational space, so rough binding modes should be pro-
vided by a method like DOCK [20].
For DOCK studies, the molecular surface (Connolly Surface) of the
binding site comprising residues 20^38 was prepared by the SYBYL
program MOLCAD, with a probe radius of 1.4 Aî . After re¢nement, a
cluster of 46 spheres was enclosed in a grid of dimensions 34U34U29
Aî 3 [17] with 0.3 Aî spacing. This grid stores the steric and electrostatic
information of the receptor atoms used for ‘force ¢eld scoring’ of the
orientations determined by DOCK. Both ‘rigid’ and ‘£exible’ docking
of the molecules was carried out with the protocol described in the
DOCK manual.
The docking protocol in A⁄nity is based on Monte Carlo and
Simulated Annealing techniques. Ligand^receptor interactions are
evaluated either by the GRID/MM method of Luty et al. [21], which
also incorporates the solvation model of Stouten et al. [22]. The dock-
ing procedure followed in A⁄nity was as prescribed in the manual.
3. Results and discussion
All possible binding orientations for D- and L-penicillamine
clustered in two main regions, which we label as A and B. The
amino acid residues composing these sites are listed in Table
1. A 6 Aî radius from the center of mass of the inhibitor was
used to de¢ne these sites.
The results given in Table 2 indicate that DOCK is unable
to really distinguish between the two isomers, their estimation
of binding energies is very nearly the same. This is not sur-
prising, since as mentioned earlier, DOCK does not use a very
Fig. 1. Binding orientation of D-penicillamine (green) and L-penicillamine (brown) in region A of HIV-1 tat protein. The cysteine-rich region of
the protein has been drawn as a ribbon, the residues of region A in the protein are also indicated.
Table 1
Composition of sites A and B and H-bonds between inhibitora and residues in the binding site
Isomer of penicillamine Site A residues/H-bonds Site B residues/H-bonds
D Trp11, Asn12, Ala21, Cys22, Asn23, Arg24 Pro10, Trp11, Asn12, Ala21, Cys22, Asn23, Arg24, Gln35, Val36
N8TH-N(Cys22) N8ThH-N(Arg24)
H5TONC(Cys22) H5TONC(Cys22)
L Asn12, Thr20, Ala21, Cys22, Asn23, Arg24 Pro10, Trp11, Asn12, Cys22, Asn23, Arg24, Gln35, Val36
N8TH-N(Cys22) N8TH-N(Val36)
H5TONC(Cys22) H82ThH-N(Arg24)
O7TOH-N(Gln35)
aThe atoms of penicillamine have been labelled in Fig. 3.
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accurate force ¢eld for the energy estimation. The two ‘DOCK
best scored structures’ for both the isomers were then sub-
jected to more accurate binding studies by A⁄nity.
The results of A⁄nity studies are summed up in Table 2. It
is evident from this table that the true binding energies of the
D- and L-isomers in both regions A and B are clearly di¡er-
entiated, with the D-isomer predicted to bind more ¢rmly than
the L-form. It can also be seen that, for both isomers, site A is
preferred over B for binding. At site A, the D-isomer is seen to
bind more ¢rmly by about 3.7 kcal/mol, while the di¡erentia-
tion extends to almost 9.7 kcal/mol at site B. A break-up of
the components of the binding energy for the D- and L-isomers
shows that it is mainly the van der Waals interaction which
accounts for the di¡erences in their binding energies. A care-
ful inspection reveals that the D-isomer has a more favorable
van der Waals interaction resulting from an optimal place-
ment of the dimethylthiomethyl side chain in the binding
site. This is visible in Figs. 1 and 2, where the binding orien-
tations for both D- and L-penicillamine in the tat protein bind-
ing sites A and B have been depicted.
The H-bonds made by the inhibitors with transactivator
protein are also mentioned in Table 1. H-bonding with
Fig. 2. Binding orientation of D-penicillamine (green) and L-penicillamine (brown) in region B of HIV-1 tat protein. The cysteine-rich region of
the protein has been drawn as a ribbon, the residues of region B in the protein are also indicated.
Table 2
Binding energies of D- and L-penicillamine by DOCK and A⁄nity
Region Energy (kcal/mol)
DOCK 4.0 A⁄nity
D-Penicillamine L-Penicillamine D-Penicillamine L-Penicillamine
VDW Ele Total VDW Ele Total VDW Ele Total VDW Ele Total
A 312.1 32.3 314.4 311.7 32.9 314.6 35.4 36.1 311.5 31.8 36.0 37.8
B 310.6 33.2 313.8 310.7 33.1 313.8 3.3 33.2 0.1 12.7 32.9 9.8
Table 3
E¡ects of D- and L-penicillamine on LTR (HIV-1)-directed CAT expression catalyzed by the tat protein
Experiment pg CAT/10 Wg protein
D-Penicillamine L-Penicillamine
Without penicillamine 8200 þ 905
With penicillamine (mM) 0.066 1025 þ 117 7896 þ 817
0.132 688 þ 64 5305 þ 590
0.198 516 þ 57 3977 þ 305
0.264 344 þ 29 2665 þ 246
The values are means þ S.E.M. from three experiments, each experiment involving three individual transfections (total number of values = 9).
Experimental details are described under Section 2.
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Cys22 is predominant, suggesting reaction with this residue
through covalent linkages may very likely be contributing to
the means of inhibition of these compounds.
The identi¢cation of the putative binding modes for both
the D- and L-forms of penicillamine using DOCK and A⁄nity
is in favor of the experimental observations. The transactiva-
tion of LTR (HIV-1) by the tat protein was studied in Jurkat
cells in the presence of D- and L-penicillamine. The expression
of CAT gene linked to LTR (HIV-1) was a measure of trans-
activation. As follows from Table 3, both the isomers were
able to inhibit the tat-mediated transactivation; however, D-
penicillamine, especially at low concentrations, has a far bet-
ter inhibitory potential. The selectivity of the penicillamine
e¡ect on the transactivation is documented by the cell-toxicity
studies, reported earlier [23]. Both the isomers of penicillamine
had no e¡ect on the growth of H9 cells, a human T-cell line
(ATCC HTB 176), at a concentration as high as 1 mM; only
at very high concentrations inhibition of cell growth was ob-
served. Based on these [23] cytotoxic data, we have calculated
the selectivity index (SI). SI is the quotient obtained by divid-
ing the concentration (mM) exhibiting a 50% cytotoxicity
(CD50) by the concentration inhibiting gene transactivation
to 50% (ID50) ; the SI (CD50/ID50) for D-penicillamine was
calculated to be 117.77 and for L-penicillamine was 21.96.
Based on these calculations one can conclude that the D-pen-
icillamine e¡ect on transactivation is, indeed, due to its selec-
tive interaction with the tat molecule.
The observations reported here help to understand the be-
havior of the two isomers towards the receptor and their
activities. It matches the experimental data that D-penicill-
amine is a more potent inhibitor of tat-mediated transactiva-
tion than the L-isomer. The L-isomer, even in traces, is highly
toxic due to its incorporation into cellular proteins [24]. The
neurotoxicity of L-penicillamine is well documented in the
literature [25^27]. On the other hand, D-penicillamine is being
used since 1956 as a therapeutical agent in the long-term treat-
ment of Wilson’s disease, cystinuria, rheumatoid arthritis, pri-
mary biliary cirrhosis and heavy metal poisoning [28]. The
docking studies could be of great help in predicting structures
which could be applicable to block transactivation, leading to
the search for better inhibitors of HIV-1 replication.
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